Canntab: All about the Cannabis Pill

The Canadian Cannabis market peaked – using the Canadian Marijuana Index – in early January of 2018. The Index topped 1000. It dropped a bit from there and, the Monday before legalization on Wednesday, October 17, touched 858. The index is now hovering around 500. Reality has caught up with the recreational marijuana business and the market caps of many of the producer stocks are adjusting downward to reflect that reality. read more

White Gold Corp. Extends Discovery Hole to 22.5 g/t Gold and 154.0 g/t Silver over 30.5m, Trenches 66.39 g/t Gold and 302 g/t Silver over 5m, including 109.9 g/t Gold and 486.4 g/t Silver over 3m Confirming Zone Continuity on Vertigo, JP Ross

White Gold Corp. (TSX.V: WGO, OTC – Nasdaq Intl: WHGOF, FRA: 29W) (the “Company) is pleased to announce additional Reverse Circulation (“RC”) drill results and trenching results from the Vertigo target on the JP Ross property, Yukon, Canada. These results included a significant extension of the discovery Reverse-Air-Blast (“RAB”) drill hole which extended the mineralization at depth and encountered a deeper zone of high-grade gold. The trenching performed further defined the mineralization at Vertigo and will allow the previously identified gold zones to be extrapolated to additional drill targets. read more

FSD Pharma Announces Collaboration and License Agreement with World Class Extractions

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9), which, through its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), is a licensed producer pursuant to the Cannabis Act, announced today that it has entered into a definitive Collaboration and License Agreement (the “Agreement”) with World Class Extractions Inc. (“World Class”), a company that has developed a unique extraction process designed to produce quality, potent cannabis extracts. World Class is also in the process of completing its own previously announced reverse takeover of CBD Med Research Corp. (the “RTO”), and submitted its initial listing application to the Canadian Securities Exchange (the “CSE”) late last week. read more

FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.

– FSD Pharma to work with Canntab to create tablets for the clinical research study at its facility in Cobourg, Ontario, Canada –
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab’s sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ontario with FSD Pharma in furtherance of their collaboration and license agreement dated September 17, 2018. read more

Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets

canntab, c.pill, cannabis
  • Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications.
  • The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets.
  • The study aims to show the potential for reduction or elimination of the use of opiates in patients, a major epidemic throughout North America.
  • The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.

Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”), today announces the launch of a research partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, M.D. (Head of the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at the University of British Columbia), subject to approval of the University of British Columbia where the proposed clinical trial will take place. The aim of the study is to examine and quantify the efficacy of Canntab products in decreasing the duration and quantity of postoperative use of opioid medications and in the management of preoperative pain. Dr. Garbuz shall be the Lead Investigator for the research study. read more

MGX Minerals Announces Winter Drilling Program to Target High-Grade Gold Mineralization at Depth at Fran Gold Project

CSE:XMG, MGX Minerals, lithium,

MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: 1MG / OTCQB: MGXMF) is pleased to announce that drilling will recommence shortly at its 100% owned Fran Gold Property (“Fran” or the “Property”) located 30km southwest of the Mount Milligan Gold-Copper Mine. Initial Winter 2018 drilling will drill a twin vertical hole to confirm and test below historic drill hole FR-027 from 2002. Hole FR-027 was drilled in the Hilltop Zone. Historic drill hole FR-027 assayed 13 meters of 3.76 g/t Au from 153.00m – 166.00m including 5.10 meters of 12.89 g/t Au and 18.70 g/t Au over 1.0 meter. Significant intercepts are shown in the table below (MacIntyre 2013): read more

Goldplay Closes First Tranche of Private Placement

V.GPLY, Goldplay Exploration, gold
Cision

Goldplay Exploration Ltd. (TSXV: GPLY, OTCQB: GLYXF) (“Goldplay” or the “Company”), is pleased to announce that the Company has closed the first tranche of its non-brokered private placement (the “Offering“) previously announced on November 19, 2018 and has issued 5,573,834 units for gross proceeds of $1,226,243.48. read more

MGX Minerals Enters Final Phase of Product Development for Next Generation Zinc Air Fuel Cell Systems

CSE:XMG, MGX Minerals, lithium,
Figure 1

MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: 1MG / OTCQB: MGXMF) is pleased to announce that its wholly owned subsidiary MGX Renewables, Inc. (“MGXR”) has entered the final phase of development for its next generation zinc-air mass storage systems.  All components of the system have been designed, tooled and received with the exceptions of the fuel cell and regenerator plates which comprise the housings, and the final system enclosure.  Housings are expected to arrive this month, followed by subsystem testing, this will be proceeded by system level testing in January.  All components are designed for mass production.  Many of the most sophisticated and proprietary components such as the cathode are manufactured in-house. read more

FSD Pharma Achieves Over 4 Billion Shares Traded in First 6 Months

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the Company has traded over four Billion Class B subordinate voting shares in its first six months of trading on the Canadian Securities Exchange (“CSE”). During the period of May 29, 2018 to November 29, 2018, the Company traded exactly 4,041,346,300 Class B subordinate voting shares on the CSE. This is the largest total quantity of share volume ever traded by a CSE listed issuer within one year of consecutive days of trading as confirmed by the CSE. read more